Bryce covers three considerations taking effect in January 2027—the end of Medicare Part D premium support, a faster Medicaid redetermination timeline, and the shift away from once-a-year reverification—and what they mean for patient support programs. He explores how affordability solutions can help reduce coverage disruptions, minimize unnecessary PAP utilization, and maintain continuity of therapy throughout the transition.
To learn more about AssistRx's affordability solutions, access their webinar, State of Patient Support 2026: Turning Regulatory Policy, AI and Direct-to-Patient Pressure into Program Strategy.
Read on for Bryce's insights.
Medicare, Medicaid, and Reverification: What Patient Support Programs Need to Know Before January 2027
By Bryce Aronson, Director, Business Development, AssistRx
.png)
For PSPs, this unique combination of change highlights why optimizing affordability programs with connected, configurable solutions ensures potential disruption is met with continuously supportive therapy experiences.
1. The End of Medicare Part D Premium Support
CMS recently announced the end of Medicare Part D premium subsidies—a program that has held down standalone drug plan premiums since 2025. Effective January 1, 2027, the program will sunset and the standard deductible will increase to $700. Roughly 25 million Medicare beneficiaries enrolled in standalone Part D plans will feel this shift. For many, it could mean opening a January bill that looks different than expected, while simultaneously managing a new deductible or a new plan they didn't choose. CMS projects that most beneficiaries will see modest increases, the increase will impact roughly three-quarters of standalone enrollees.
For patients starting a new therapy, January is the hardest month of the year to navigate benefits. A higher deductible on top of a shrinking subsidy makes it harder. Medicare's Prescription Payment Plan (M3P) can smooth that cost across the year, but smoothing only works if the patient understands it exists and meets the enrollment deadline. That puts pressure on PSPs to build M3P education into standard program design. The AssistRx Advanced Insurance Assistance solution is built to address this gap: dedicated navigators who help patients find and keep coverage across commercial, Medicare, Medicaid and the Marketplace, and who educate patients directly on affordability options like M3P, LIS and federal and state assistance programs before a coverage gap turns into an unfilled prescription.
2. A Faster Medicaid Redetermination Timeline
Also beginning January 1, all states will be required to complete Medicaid eligibility redeterminations every six months. This process can separately affect whether a patient is excluded from patient assistance program (PAP) support, or whether eligibility into Medicare Savings Programs (MSP) -linked affordability options apply.
Because many PAPs exclude patients with full Medicaid coverage, more frequent redeterminations could create more mid-year changes in PAP eligibility. While some patients may become genuinely ineligible, some coverage loss will trace back to missed notices or administrative friction rather than an actual change in circumstances. For life sciences organizations, that could mean increased utilization of PAPs by patients who find themselves ineligible.
AssistRx ePAP, inclusive of its non-commercial specialty pharmacy, eCoverage and eIncome Verification capabilities, meets these changes head on with real-time PAP verification and configurable eligibility rules that catch a Medicaid-to-PAP transition as it happens.
3. Rethinking Reverification's Once-a-Year "Blizzard"
For many life sciences organizations, reverification is a seasonal event. Sometimes referred to as the "Blizzard," this annual crunch forces PSPs to staff up quickly, floods payer phone lines and can leave patients exposed to affordability challenges. For example, a patient who assumes their coverage is unchanged may receive a rejected claim or a bill they didn't budget for, and at the same time, they're potentially absorbing the Part D and Medicaid changes from the new year. Further, a plan can change, a patient can lose eligibility, or a policy detail can shift months into therapy, leaving patients with coverage on the PAP until the next annual reverification cycle.
Programs that have moved reverification to a continuous, technology-enabled model see fewer of those surprises reach the patient and fewer patients on PAP unnecessarily. AssistRx Advanced Benefit Verification (ABV) uses real-time benefit data to allow reverification to run continuously instead of compressing into a once-a-year effort, giving PSPs a way to catch a coverage change before it impacts the patients or the program.
Optimized reverification models also identify prior authorizations (PAs) before the fill is needed when insurance changes. This prevents reliance on free goods to bridge coverage gaps and ensures the PAP remains the payer of last resort. AssistRx Advanced Prior Authorization streamlines the identification of PA requirements and automates the process for both submitting PAs and receiving decisions.
The AssistRx Difference
The upcoming Part D premium subsidy loss, a faster Medicaid redetermination period and a reverification process running on a once-a-year blizzard are three opportunities for life sciences organizations to reconsider how their affordability programs are built. Each has a common thread: affordability support that works continuously to help patients navigate through disruption year-round.
Learn how AssistRx can help your program prepare for the affordability shifts coming in 2027 and more: access the webinar, State of Patient Support 2026: Turning Regulatory Policy, AI and Direct-to-Patient Pressure into Program Strategy.
Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Marie Caldwell (mcaldwell@hmpglobal.com).
No comments:
Post a Comment